Nivesh H Sewlall Guy Richards Adriano Duse Robert Swanepoel Janusz Paweska Lucille Blumberg Thu Ha Dinh Daniel Bausch
10.1371/journal.pntd.0003233
PLoS Negl Trop Dis
2014 Nov 13;8(11):e3233.
CC0
https://pubmed.ncbi.nlm.nih.gov/25393244/
Antiviral Agents / therapeutic use Arenaviridae Infections / pathology Cross Infection / pathology Disease Outbreaks Hemorrhagic Fevers, Viral / pathology Lujo virus / isolation & purification
Antiviral Agents / therapeutic use Arenaviridae Infections / pathology Cross Infection / pathology Disease Outbreaks Hemorrhagic Fevers, Viral / pathology Lujo virus / isolation & purification Case Reports Acetylcysteine / therapeutic use Adult Arenaviridae Infections / drug therapy Arenaviridae Infections / epidemiology Arenaviridae Infections / virology Cross Infection / drug therapy Cross Infection / epidemiology Cross Infection / virology Factor VIIa / therapeutic use Fatal Outcome Female Hemorrhagic Fevers, Viral / drug therapy Hemorrhagic Fevers, Viral / epidemiology Hemorrhagic Fevers, Viral / virology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Lassa Fever / pathology Lassa virus / isolation & purification Lujo virus / drug effects Male Middle Aged Recombinant Proteins / therapeutic use Ribavirin / therapeutic use South Africa / epidemiology Antiviral Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Recombinant Proteins Ribavirin recombinant FVIIa Factor VIIa Acetylcysteine
PMC4230886
25393244
Clinical features and patient management of Lujo hemorrhagic fever
2014